AIDS OPPORTUNISTIC INFECTIONS DRUG DESIGN

艾滋病机会性感染药物设计

• 批准号: 6658721
• 负责人: DAVID W BORHANI
• 金额: $ 14.32万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-01 至 2003-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6658721
• 关键词: AIDS; bioimaging /biomedical imaging; biomaterials; biomedical resource; immunology; infection; inflammation; lymphatic system; proteins; radiography; structural biology; virus

Pneumocystis carinii pneumonia (PCP) is the leading killer of patients with AIDS. Similarly, Toxomplasma gondii, a pervasive parasitic protozoan, causes significant morbidity and mortality among AIDS patients. Current treatment regimens for both P. carinii and T. gondii infections often produce severe side effects, leading to the cessation of therapy. It is widely recognized that new drugs having novel mechanisms of action are urgently needed for the treatment of PCP and toxoplasmosis. Building upon prior medicinal chemistry research, we have initiated two structure-based drug design programs to make improved inhibitors of T. gondii hypoxanthine-guanine phosphoribosyltransferase (HGPRT), T. gondii dihydrofolate reductase-thymidylate synthase (DHFR-TS) and P. carinii DHFR.

卡氏肺孢子虫肺炎（PCP）是导致 艾滋病患者。 同样，弓形虫，一种普遍存在的 寄生原生动物，造成重大的发病率和死亡率， 艾滋病患者。 卡氏肺孢子虫和弓形虫目前的治疗方案。 弓形虫感染通常会产生严重的副作用， 停止治疗。 人们普遍认为， 迫切需要新的作用机制来治疗 PCP和弓形虫病。 基于先前的药物化学 研究，我们已经启动了两个基于结构的药物设计计划 来制造T.弓形虫次黄嘌呤鸟嘌呤 磷酸核糖基转移酶（HGPRT）、T.二氢叶酸弓形虫 还原酶-胸苷酸合酶（DHFR-TS）和卡氏肺吸虫DHFR。